One in five women in WHO Southeast Asia region covered under health insurance, study estimates
WHO Southeast Asia Region
, including India, are covered under a health insurance, a study published in The Lancet Regional Health Southeast Asia has estimated.
One in eight women in the region - defined by the World Health Organization (WHO) - were enrolled in social security schemes. At the same time, only one in thirteen had privately purchased or commercial insurance, the analysis reveals.
The 'WHO Southeast Asia Region' includes India, among other countries such as Bangladesh, Myanmar and Indonesia.
Researchers from Health Systems Transformation Platform and Population Council Consulting Private Limited, New Delhi, also found that one in four men in the region had health insurance coverage, with the highest prevalence seen in Indonesia at over 56 per cent and lowest in Myanmar at about 1.5 per cent.
In India, the prevalence of health insurance uptake was 53 per cent among women and 56 per cent among men, the team found.
The highest levels of health insurance coverage for women and men in the region were found in Indonesia, while the lowest levels were reported in Bangladesh and Myanmar, respectively.
Equity in accessing quality healthcare without experiencing financial hardship is key to achieving
Universal Health Coverage
(UHC) - one of the core aims of the United Nations' Sustainable Development Goals - especially in low- and middle-income countries in the WHO Southeast Asia Region, the authors of the study said.
They added that healthcare demands and costs are expected to rise in the region as populations age. However, high out-of-pocket expenditures remain a barrier despite health insurance programmes in the region, they said.
The study analysed socioeconomic and demographic factors to estimate coverage under any health insurance, using data from Demographic and Health Surveys (2015-2022) conducted in the WHO Southeast Asia Region every five years.
"Approximately one in five women in the region were covered by any form of health insurance," the authors wrote.
"In contrast, one in four men in the region had any health insurance coverage, with the highest prevalence observed in Indonesia (56.6 per cent) and the lowest in Myanmar (1.4 per cent)," they wrote.
Older age, higher education levels, and higher exposure to media were found to positively influence insurance coverage for both men and women in India, Indonesia, Nepal, Bangladesh and Myanmar.
Further, beyond individual factors, contextual ones such as government commitment, design and implementation of insurance schemes and economic conditions are crucial in determining health insurance coverage, the authors said.
Traditional beliefs and a lack of trust in formal financial systems can hinder insurance adoption among South Asian communities, they added.
Evidence suggests that in rural areas of India, Nepal and Bangladesh, people relied on community-based informal support systems over formal insurance, reflecting cultural preferences that affect enrolment rates, the team said.
The study's findings, therefore, highlight that country-specific contexts need to be addressed to effectively expand health insurance coverage, the authors said.
They suggested policies should prioritise building sustainable health financing systems, making healthcare infrastructures more resilient, and fostering widespread awareness in the community about the benefits of health insurance.
Further, strategies aimed at resolving socioeconomic disparities and for the underinsured populations are vital in advancing equitable health insurance access and accelerating progress towards UHC, the team said. PTI
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
WHO recommends a twice-a-year injection for HIV prevention
The World Health Organization is now recommending that countries include a newly approved HIV drug for prevention, lenacapavir, as a tool in their efforts to fight HIV infections, especially for groups most at risk and in areas where the burden of HIV remains high. This landmark guidance, released at the 13th International AIDS Society Conference in Kigali on July 14 – as concern looms over funding for the global HIV fight – endorses the drug's use every six months, marking a pivotal shift from daily pills to long‑acting, needle‑delivered protection. What is Lenacapavir? Lenacapavir (brand names Sunlenca for treatment, Yeztugo for prevention) is a long‑acting capsid inhibitor that has redefined HIV prevention. Administered via injection just twice a year, it works by targeting the structural protein (capsid) of the HIV, blocking its ability to replicate in the body. Lenacapavir was approved in 2022 to treat certain HIV infections, and in trials for prevention, it was found to dramatically reduce the risk of infection and provide almost total protection against HIV. WHO's official recommendation Dr. Meg Doherty, director of WHO's Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes, said in a news briefing, 'These new recommendations are designed for real-world use. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Is it legal? How to get Internet without paying a subscription? Techno Mag Learn More Undo WHO is working closely with countries and partners to support the implementation.' Doherty added, 'The first recommendation is that a long-acting injectable, lenacapavir, should be offered as an additional prevention choice for people at risk for HIV and as part of combination prevention. With that, we call it a strong recommendation with moderate to high certainty of the evidence.' The second recommendation in the guidelines is that rapid diagnostic tests, like at-home tests, can be used to screen someone for HIV when they are starting, continuing, or stopping long-acting medication to prevent infection, called pre-exposure prophylaxis, or PrEP. Health leaders, including WHO's Director‑General Dr. Tedros Adhanom Ghebreyesus, touted lenacapavir as 'the next best thing' to an HIV vaccine. This latest endorsement complements existing WHO‑approved prevention methods – daily oral PrEP, bi‑monthly cabotegravir injections, and the dapivirine vaginal ring. WHO also streamlined HIV testing protocols to support injectable PrEP uptake in community settings, pharmacies, and telehealth contexts. Why a twice‑yearly injection might prove to be a good shot Adherence and convenience: Daily pill demands consistency, which many at‑risk individuals struggle to maintain. Lenacapavir simplifies prevention to two clinic visits per year, helping sidestep barriers like stigma, pill fatigue, or limited healthcare access. Effectiveness: Purpose trial data speaks volumes: in one study, zero infections occurred among participants receiving lenacapavir, compared to significant infection rates in the pill‑based PrEP group. Equity and access: High‑risk populations – sex workers, LGBTQ+ individuals, people who inject drugs, incarcerated people, adolescents – stand to gain most from an easy‑to‑administer, long‑lasting prevention tool. What is HIV/AIDS? HIV (human immunodeficiency virus) is a virus that attacks cells that help the body fight infection, making a person more vulnerable to other infections and diseases. It is spread by contact with certain bodily fluids of a person with HIV, most commonly during unprotected sex (sex without a condom or HIV medicine to prevent or treat HIV), or through sharing injection drug equipment. If left untreated, HIV can lead to the disease AIDS (acquired immunodeficiency syndrome). Within a few weeks of HIV infection, flu-like symptoms such as fever, sore throat, and fatigue can occur. Then the disease is usually asymptomatic until it progresses to AIDS. AIDS symptoms include weight loss, fever or night sweats, fatigue, and recurrent infections. There is no existing cure for AIDS, but strict adherence to antiretroviral regimens (ARVs) can dramatically slow the disease's progress as well as prevent secondary infections and complications. Vaccines for HIV are under trial, but no effective vaccine has been developed to date. In early 2025, the global fight against HIV/AIDS faced a significant setback with the United States of America's decision to halt foreign aid funding for HIV prevention and treatment programs. This move, part of a broader 90-day pause in US foreign development assistance, sent shockwaves through the international health community only a week ago, raising alarms about a potential resurgence of the epidemic. WHO's endorsement of twice‑yearly lenacapavir marks a transformative moment, especially amidst the looming concerns regarding the funding cuts. Gilead Sciences, maker of lenacapavir, recently announced that it has reached an agreement with the nonprofit Global Fund to Fight AIDS, Tuberculosis and Malaria to supply lenacapavir for HIV prevention at no profit to the company. Under this agreement, Gilead's pricing reflects only the cost of producing and delivering lenacapavir. Gilead Chairman and CEO Daniel O'Day said in a news release, 'We are providing the medicine at no profit to Gilead, and in enough supply to reach up to two million people in low- and lower-middle-income countries ahead of generic lenacapavir becoming available.' Peter Sands, executive director of the Global Fund, said in the news release, lenacapavir can 'fundamentally change the trajectory of the HIV epidemic,' but only if it reaches the people who need it most. As per him, 'Our ambition is to reach 2 million people with long-acting PrEP. But we can only do that if the world steps up with the resources required. This is a pivotal moment — not just for the fight against HIV, but for the fundamental principle that lifesaving innovations must reach those who need them most — whoever they are, and wherever they live.' If scaled equitably and thoughtfully, this intervention could reshape the landscape of HIV prevention, moving us closer to a world without AIDS. Actor Nargis Fakhri Reveals 9‑Day Water Fast Twice a Year to Get 'Snatched'
Time of India
an hour ago
- Time of India
UN says 14 million children did not receive a single vaccine in 2024
London: More than 14 million children did not receive a single vaccine last year - about the same number as the year before - according to UN health officials. Nine countries accounted for more than half of those unprotected children. In their annual estimate of global vaccine coverage , released Tuesday, the World Health Organization and UNICEF said about 89 per cent of children under one year old got a first dose of the diphtheria, tetanus and whooping cough vaccine in 2024, the same as in 2023. About 85 per cent completed the three-dose series, up from 84 per cent in 2023. Officials acknowledged, however, that the collapse of international aid this year will make it more difficult to reduce the number of unprotected children. In January, US President Trump withdrew the country from the WHO, froze nearly all humanitarian aid and later moved to close the US AID Agency. And last month, Health Secretary Robert F. Kennedy Jr. said it was pulling the billions of dollars the US had previously pledged to the vaccines alliance Gavi, saying the group had "ignored the science". Kennedy, a longtime vaccine skeptic, has previously raised questions the diphtheria, tetanus and whooping cough vaccine - which has proven to be safe and effective after years of study and real-world use. Vaccines prevent 3.5 million to 5 million deaths a year, according to UN estimates. "Drastic cuts in aid, coupled with misinformation about the safety of vaccines, threaten to unwind decades of progress," said WHO Director-General Tedros Adhanom Ghebreyesus. UN experts said that access to vaccines remained "deeply unequal" and that conflict and humanitarian crises quickly unraveled progress; Sudan had the lowest reported coverage against diphtheria, tetanus and whooping cough. The data showed that nine countries accounted for 52 per cent of all children who missed out on immunisations entirely: Nigeria, India, Sudan, Congo, Ethiopia, Indonesia, Yemen, Afghanistan and Angola. WHO and UNICEF said that coverage against measles rose slightly, with 76 per cent of children worldwide receiving both vaccine doses. But experts say measles vaccine rates need to reach 95 per cent to prevent outbreaks of the extremely contagious disease. WHO noted that 60 countries reported big measles outbreaks last year. The US is now having its worst measles outbreak in more than three decades, while the disease has also surged across Europe, with 1,25,000 cases in 2024 - twice as many as the previous year, according to WHO. Last week, British authorities reported a child died of measles in a Liverpool hospital. Health officials said that despite years of efforts to raise awareness, only about 84 per cent of children in the UK are protected. "It is hugely concerning, but not at all surprising, that we are continuing to see outbreaks of measles," said Helen Bradford, a professor of children's health at University College London. "The only way to stop measles spreading is with vaccination," she said in a statement. "It is never too late to be vaccinated - even as an adult."
Indian Express
2 hours ago
- Indian Express
14 million children did not receive a single vaccine in 2024, UN estimates
More than 14 million children did not receive a single vaccine last year — about the same number as the year before — according to U.N. health officials. Nine countries accounted for more than half of those unprotected children. In their annual estimate of global vaccine coverage, released Tuesday, the World Health Organization and UNICEF said about 89% of children under 1 year old got a first dose of the diphtheria, tetanus and whooping cough vaccine in 2024, the same as in 2023. About 85% completed the three-dose series, up from 84% in 2023. Officials acknowledged, however, that the collapse of international aid this year will make it more difficult to reduce the number of unprotected children. In January, U.S. President Trump withdrew the country from the WHO, froze nearly all humanitarian aid and later moved to close the U.S. AID Agency. And last month, Health Secretary Robert F. Kennedy Jr. said it was pulling the billions of dollars the U.S. had previously pledged to the vaccines alliance Gavi, saying the group had 'ignored the science.' Kennedy, a longtime vaccine skeptic, has previously raised questions the diphtheria, tetanus and whooping cough vaccine — which has proven to be safe and effective after years of study and real-world use. Vaccines prevent 3.5 million to 5 million deaths a year, according to U.N. estimates. 'Drastic cuts in aid, coupled with misinformation about the safety of vaccines, threaten to unwind decades of progress,' said WHO Director-General Tedros Adhanom Ghebreyesus. U.N. experts said that access to vaccines remained 'deeply unequal' and that conflict and humanitarian crises quickly unraveled progress; Sudan had the lowest reported coverage against diphtheria, tetanus and whooping cough. The data showed that nine countries accounted for 52% of all children who missed out on immunizations entirely: Nigeria, India, Sudan, Congo, Ethiopia, Indonesia, Yemen, Afghanistan and Angola. WHO and UNICEF said coverage against measles rose slightly, with 76% of children worldwide receiving both vaccine doses. But experts say measles vaccine rates need to reach 95% to prevent outbreaks of the extremely contagious disease. WHO noted that 60 countries reported big measles outbreaks last year. The U.S. is now having its worst measles outbreak in more than three decades, while the disease has also surged across Europe, with 125,000 cases in 2024 — twice as many as the previous year, according to WHO. Last week, British authorities reported a child died of measles in a Liverpool hospital. Health officials said that despite years of efforts to raise awareness, only about 84% of children in the U.K. are protected. 'It is hugely concerning, but not at all surprising, that we are continuing to see outbreaks of measles,' said Helen Bradford, a professor of children's health at University College London. 'The only way to stop measles spreading is with vaccination,' she said in a statement. 'It is never too late to be vaccinated — even as an adult.'
